Annexon, Inc.

74 articles about Annexon, Inc.

• Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Aug 17, 2022

  8/17/2022

  Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced that it has granted equity inducement awards to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

• 

  Can AAV Gene Therapy Transcend Challenges in the Huntington's Space?

  7/13/2022

  uniQure gave a 12-month update on AMT-130, the first-ever AAV gene therapy for HD to enter clinical trials. BioSpace spoke with the company's president of R&D, Dr. Ricardo Dolmetsch.
• 

  Pliant and Annexon Seek and Secure Funds for Pulmonary Fibrosis, Autoimmune Treatments

  7/12/2022

  Annexon and Pliant Therapeutics both made efforts to secure additional financing to support their R&D endeavors.

• Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025

  7/11/2022

  Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced the closing of its private placement, resulting in gross proceeds of approximately $130 million, before deducting placement agent fees and other expenses.

• 

  Annexon Engages the Target, Sees Stabilization in Phase II Huntington's Trial

  6/8/2022

  Annexon released final data from an open-label phase II clinical trial, showing that its drug candidate ANX005 safely stabilized disease progression in patients with Huntington’s disease.

• Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease

  6/7/2022

  Annexon, Inc. announced promising, final data from its open-label Phase 2 clinical trial of ANX005 in patients with Huntington’s disease.

• Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference

  6/2/2022

  Annexon, Inc. announced that Douglas Love, Esq., president and chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET in New York City.

• Annexon Biosciences to Participate in Upcoming May 2022 Investor Conferences

  5/5/2022

  Annexon, Inc. announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following May investor conferences:

• 

  Octant Scores $80M in Series B Funds, Partnership with BMS

  4/21/2022

  Octant announced an $80 million Series B financing round, a Deep Mutual Scanning (DMS) biopharma partnership with Bristol Myers Squibb and key appointments to its leadership.
• 

  Clinical Catch-Up: COVID-19, AAN, ACC

  4/11/2022

  It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.

• Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy

  4/7/2022

  Annexon, Inc. announced the completion of enrollment in the Phase 2 ARCHER trial evaluating its anti-C1q candidate, ANX007, in patients with geographic atrophy.

• Annexon Biosciences to Participate in the 21st Annual Needham Virtual Healthcare Conference

  4/4/2022

  Annexon, Inc. announced that Douglas Love, Esq., president & chief executive officer, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022 at 3:45 p.m. ET.

• Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington’s Disease at AAN 2022

  3/3/2022

  Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced that the company will present preclinical data highlighting its approach of inhibiting C1q to address a number of complement-mediated diseases.

• Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results

  3/1/2022

  Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced recent highlights and reported fourth quarter and full year 2021 financial results.

• Annexon Biosciences to Participate in the Cowen 42nd Annual Healthcare Conference

  2/28/2022

  Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced that Douglas Love, Esq., president and chief executive officer, will participate in a virtual panel titled, “Orphan CNS Panel,” during the Cowen 42nd Annual Healthcare Conference.

• Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors

  1/20/2022

  Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), today announced the appointment of biotech executive Bettina M. Cockroft, M.D., senior vice president and chief medical officer of Sangamo Therapeutics, Inc., to the company’s board of directors.

• 

  Annexon Data Demonstrates Potential of C1q Inhibition in Huntington’s Disease

  1/5/2022

  An improvement in cUHDRS was observed in more than half of all evaluable patients and was specifically seen in 75% of the evaluable population who showed excess complement activity at baseline.

• Annexon Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/4/2022

  Annexon, Inc. today announced that Douglas Love, Esq., President & Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 3:45 p.m. ET.

• Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington’s Disease Following Six-Month Treatment

  1/4/2022

  Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing medicines that stop destructive immune activity in complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced interim data from its ongoing, open-label Phase 2 clinical trial of ANX005 in patients with Huntington’s disease (HD) who completed the 24-week treatment period.

• Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition

  12/13/2021

  Annexon, Inc. (Nasdaq: ANNX), announced safety and dose-response data from its Phase 1 clinical trial of ANX009, the company’s subcutaneously administered product candidate that is designed to block the activity of C1q and the entire classical complement pathway.